Muranishi S
Kyoto Pharmaceutical University, Japan.
Yakugaku Zasshi. 1997 Jul;117(7):394-414. doi: 10.1248/yakushi1947.117.7_394.
Most people drugs are hydrophilic molecules with a molecular weight between 300 and 20,000 and such molecules are usually given by parenteral administration. In many cases, enteral administration of these peptides via the gastrointestinal tract is preferred. However, oral administration of peptides and proteins is often limited by their instability in the gastrointestinal environment and/or poor absorption from the gut. To promote the absorption of these drugs, we first discovered unsaturated fatty acids with absorption enhancing activities and less harmful properties to the gastrointestinal membranes in hydrolysates of natural oil. The mechanisms whereby the permeability of drugs was enhanced by the fatty acids are associated with the disorder in the membrane's interior and the interaction of these fatty acids with the polar head group of phospholipid. Furthermore, we suggested that a SH-related substance was involved in the permeability enhancing effect of these fatty acids. Secondly, we developed a lympho-targeting delivery system for bleomycin by the combined effects of an ion-pair complex with dextran sulfate (DS) and an absorption enhancer. We found a very high lymphatic concentration when administered bleomycin-DS together with the absorption enhancer. Its mechanism may be due to a molecular sieving in the blood-lymph barrier in the intestinal tissues. Finally, to improve the intestinal absorption of peptides, we synthesized novel lipophilic derivatives of peptides including TRH (thyrotropin releasing hormone), tetragastrin, enkephalin, calcitonin and insulin by a chemical modification with fatty acids, while maintaining their pharmacological activities. The stability and permeability of these peptides were improved by acylation with some fatty acids having appropriate carbon numbers. Thus, we have established the strategies for improving the delivery of peptide drugs by various approaches. In future, the combination use of these approaches will be expected to develop the delivery systems of these drugs for therapeutic treatment.
大多数药物是分子量在300至20,000之间的亲水性分子,这类分子通常通过肠胃外给药。在许多情况下,经胃肠道肠内给药是首选。然而,肽和蛋白质的口服给药常常受到其在胃肠道环境中不稳定和/或肠道吸收不良的限制。为促进这些药物的吸收,我们首先在天然油脂水解物中发现了具有吸收增强活性且对胃肠道膜危害较小的不饱和脂肪酸。脂肪酸增强药物通透性的机制与膜内部的紊乱以及这些脂肪酸与磷脂极性头部基团的相互作用有关。此外,我们认为一种与SH相关的物质参与了这些脂肪酸的通透性增强作用。其次,我们通过离子对复合物与硫酸葡聚糖(DS)以及吸收增强剂的联合作用,开发了一种针对博来霉素的淋巴靶向递送系统。当将博来霉素-DS与吸收增强剂一起给药时,我们发现其在淋巴中的浓度非常高。其机制可能是由于肠道组织中血-淋巴屏障的分子筛分作用。最后,为改善肽的肠道吸收,我们通过用脂肪酸进行化学修饰合成了包括促甲状腺激素释放激素(TRH)、胃泌素、脑啡肽、降钙素和胰岛素在内的新型肽类亲脂性衍生物,同时保持它们的药理活性。通过用一些具有适当碳原子数的脂肪酸进行酰化,这些肽的稳定性和通透性得到了改善。因此,我们已经通过各种方法建立了改善肽类药物递送的策略。未来,预计这些方法的联合使用将开发出用于治疗的这些药物的递送系统。
Yakugaku Zasshi. 1997-7
Yakugaku Zasshi. 2001-12
Adv Drug Deliv Rev. 2012-1-4
Eur J Pharm Biopharm. 2015-10
Crit Rev Ther Drug Carrier Syst. 2003